Your browser doesn't support javascript.
Neutralizing efficacy of vaccines against the SARS-CoV-2 Mu variant
Kei Miyakawa; Sundararaj Stanleyraj Jeremiah; Hideaki Kato; Akihide Ryo.
  • Kei Miyakawa; Yokohama City University School of Medicine
  • Sundararaj Stanleyraj Jeremiah; Yokohama City University School of Medicine
  • Hideaki Kato; Yokohama City University Hospital
  • Akihide Ryo; Yokohama City University School of Medicine
Preprint in English | medRxiv | ID: ppmedrxiv-21264014
ABSTRACT
The rise of mutant strains of SARS-CoV-2 poses an additional problem to the existing pandemic of COVID-19. There are rising concerns about the Mu variant which can escape humoral immunity acquired from infections from previous strains or vaccines. We examined the neutralizing efficacy of the BNT162b2 mRNA vaccine against the Mu variant and report that the vaccine has 76% neutralizing effectiveness against the Mu compared to 96% with the original strain. We also show that Mu, similar to the Delta variant, causes cell-to-cell fusion which can be an additional factor for the variant to escape vaccine-mediated humoral immunity. Despite the rise in vaccine escape strains, the vaccine still possesses adequate ability to neutralize majority of the mutants.
Full text: Available Collection: Preprints Database: medRxiv Language: English Year: 2021 Document Type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Language: English Year: 2021 Document Type: Preprint